Global Dermatology CRO Market To Witness Robust Revenue Growth Across Key Regional Pockets : Fact.MR

Market Segments Covered in Dermatology CRO Industry Analysis

• By Type :
  • Drug Discovery
    • Target Validation
    • Lead Identification
    • Lead Optimization
  • Clinical
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Preclinical
• By Service :
  • Project Management/Clinical Supply Management
  • Data Management
  • Regulatory/Medical Affairs
  • Medical Writing
  • Clinical Monitoring
  • Quality Management/Assurance
  • Bio-statistics
  • Investigator Payments
  • Laboratory
  • Patient and Site Recruitment
  • Technology
  • Other Services
• By Region :
  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Key Takeaways from the Market Study

• Global Dermatology CRO market is expected to reach a market size of US$ 4.3 Bn by 2022
• Clinical dermatology CRO is expected to be the highest revenue generating category, accounting for an absolute dollar opportunity of nearly US$ 3.5 Bn during 2022 – 2032.
• Top service being Clinical Monitoring is expected to grow at a CAGR of over 7% during 2022 – 2032.
• With nearly 10% projected growth rate, Dermatology CRO revenue is expected to grow at fastest pace in U.S in North America, during 2022 – 2032.
• The Dermatology CRO market reached a valuation of US$ 4.3 Bn in 2022 as the worldwide revenues was up by 8.6% year-over-year.

Competitive Landscape

A number of regional and global players operate in Dermatology CRO market. These companies compete based on the innovation of their products, their quality, their brand reputation, and their market presence in order to sell their products through various industries. A variety of strategies are being employed by companies to remain competitive.

• In February 2021, Icon plc agreed to purchase PRA Health Sciences for US$ 12 Bn in a formal agreement. Owing to the expanded geographic, functional, and therapeutic scale, customers will benefit from the merger.
• In 2021, Thermo Fisher agreed to purchase PPD for US$ 17.4 Bn in a contractual agreement. Thermo Fisher’s position in the clinical research services industry, particularly in the early phase clinical trials business, will be considerably strengthened as a result of this acquisition. Healthcare contract research companies are striving to expand their services globally in addition to upgrading their current offerings.
• In October 2019, Parexel extended its relations with the Society for Clinical Research Sites (SCRS), the world’s first and only organization dedicated only to the protection of clinical research sites’ interests. As a Site Engagement Partner, the business introduced a number of key initiatives aimed at improving the patient experience in clinical trials.